Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 832


Comparable outcome with T-cell-depleted unrelated-donor versus related-donor allogeneic bone marrow transplantation.

Alyea EP, Weller E, Fisher DC, Freedman AS, Gribben JG, Lee S, Schlossman RL, Stone RM, Friedberg J, DeAngelo D, Liney D, Windawi S, Ng A, Mauch P, Antin JH, Soiffer RJ.

Biol Blood Marrow Transplant. 2002;8(11):601-7.


CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.

Soiffer RJ, Mauch P, Fairclough D, Alyea E, Anderson K, Fisher D, Freedman A, Bartlett-Pandite L, Robertson M, Schlossman R, Gollob J, Marcus K, Murray C, Kuhlman C, Freeman A, Nadler L, Ritz J.

Biol Blood Marrow Transplant. 1997 Apr;3(1):11-7.


Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion.

Keever-Taylor CA, Bredeson C, Loberiza FR, Casper JT, Lawton C, Rizzo D, Burns WH, Margolis DA, Vesole DH, Horowitz M, Zhang MJ, Juckett M, Drobyski WR.

Biol Blood Marrow Transplant. 2001;7(11):620-30.


Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T-cell-depleted allogeneic marrow transplantation for chronic myelogenous leukemia.

Hessner MJ, Endean DJ, Casper JT, Horowitz MM, Keever-Taylor CA, Roth M, Flomenberg N, Drobyski WR.

Blood. 1995 Nov 15;86(10):3987-96.


T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation.

Drobyski WR, Hessner MJ, Klein JP, Kabler-Babbitt C, Vesole DH, Margolis DA, Keever-Taylor CA.

Blood. 1999 Jul 15;94(2):434-41. Erratum in: Blood 2000 Feb 15;95(4):1137.


Use of partially mismatched related donors extends access to allogeneic marrow transplant.

Henslee-Downey PJ, Abhyankar SH, Parrish RS, Pati AR, Godder KT, Neglia WJ, Goon-Johnson KS, Geier SS, Lee CG, Gee AP.

Blood. 1997 May 15;89(10):3864-72.


CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission.

Soiffer RJ, Fairclough D, Robertson M, Alyea E, Anderson K, Freedman A, Bartlett-Pandite L, Fisher D, Schlossman RL, Stone R, Murray C, Freeman A, Marcus K, Mauch P, Nadler L, Ritz J.

Blood. 1997 Apr 15;89(8):3039-47.


Effect of total body irradiation dose escalation on outcome following T-cell-depleted allogeneic bone marrow transplantation.

Alyea E, Neuberg D, Mauch P, Marcus K, Freedman A, Webb I, Anderson K, Schlossman R, Fisher D, Gribben J, Ritz J, Soiffer R.

Biol Blood Marrow Transplant. 2002;8(3):139-44.


Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation.

Weisdorf DJ, Anasetti C, Antin JH, Kernan NA, Kollman C, Snyder D, Petersdorf E, Nelson G, McGlave P.

Blood. 2002 Mar 15;99(6):1971-7.


Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia.

Drobyski WR, Ash RC, Casper JT, McAuliffe T, Horowitz MM, Lawton C, Keever C, Baxter-Lowe LA, Camitta B, Garbrecht F, et al.

Blood. 1994 Apr 1;83(7):1980-7.


Association of donor-derived host-reactive cytolytic and helper T cells with outcome following alternative donor T cell-depleted bone marrow transplantation.

Keever-Taylor CA, Passweg J, Kawanishi Y, Casper J, Flomenberg N, Baxter-Lowe LA.

Bone Marrow Transplant. 1997 May;19(10):1001-9.


Bone marrow transplantation for chronic myeloid leukemia (CML) from unrelated and sibling donors: single center experience.

Lamparelli T, Van Lint MT, Gualandi F, Occhini D, Barbanti M, Sacchi N, Ficai G, Ghinatti C, Ferrara GB, Delfino L, Pozzi S, Morabito A, Zikos P, Vitale V, Corvo R, Frassoni F, Bacigalupo A.

Bone Marrow Transplant. 1997 Dec;20(12):1057-62.


Bone marrow transplantation for chronic myeloid leukemia with volunteer unrelated donors using ex vivo or in vivo T-cell depletion: major prognostic impact of HLA class I identity between donor and recipient.

Spencer A, Szydlo RM, Brookes PA, Kaminski E, Rule S, van Rhee F, Ward KN, Hale G, Waldmann H, Hows JM, Batchelor JR, Goldman JM.

Blood. 1995 Nov 1;86(9):3590-7. Review.


Relapse after non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: early transplantation, use of an unrelated donor, and chronic graft-versus-host disease are protective.

Enright H, Davies SM, DeFor T, Shu X, Weisdorf D, Miller W, Ramsay NK, Arthur D, Verfaillie C, Miller J, Kersey J, McGlave P.

Blood. 1996 Jul 15;88(2):714-20.


Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft.

Lee CK, deMagalhaes-Silverman M, Hohl RJ, Hayashi M, Buatti J, Wen BC, Schlueter A, Strauss RG, Gingrich RD.

Bone Marrow Transplant. 2003 Jan;31(2):121-8.


Allogeneic transplantation of G-CSF mobilized peripheral blood stem cells from unrelated donors: a retrospective analysis.

Bornhäuser M, Theuser C, Soucek S, Hölig K, Klingebiel T, Blau W, Fauser A, Runde V, Schwinger W, Rutt C, Ehninger G.

Haematologica. 2000 Aug;85(8):839-47.


Single-centre experience with allogeneic bone marrow transplantation for acute lymphoblastic leukaemia in childhood: similar survival after matched-related and matched-unrelated donor transplants.

Al-Kasim FA, Thornley I, Rolland M, Lau W, Tsang R, Freedman MH, Saunders EF, Calderwood S, Doyle JJ.

Br J Haematol. 2002 Feb;116(2):483-90.


Supplemental Content

Support Center